Drug Trial Radar · NCT06208748
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Last checked: Nov 20, 2026Latest source record: Oct 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 1, 2024
Primary completion
Jun 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Sarcoma Alliance for Research through CollaborationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cogent Biosciences, Inc.; Dana-Farber Cancer Institute; The Life Raft Group
- First posted
- Jan 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
Conditions
- Gastrointestinal Stromal Tumors
- GIST
Interventions
Bezuclastinib in combination with sunitinibDrug
Bezuclastinib in combination with sunitinib (sutent)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To estimate the median progression free survival (mPFS)Time frame: From the time of first dose to the occurrence of disease progression (as accessed by mRECIST v1.1) or death due to any cause prior to documented disease progression, up to 2 years..
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Sylvester Comprehensive Cancer Center, University of Miami
Miami, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
Oregon Health & Science University
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.